FABP4 and metabolic dysfunction-associated steatohepatitis: Targeting LSECs to alleviate fibrosis through one of these 4 genes could be an option as it was recently shown that the treatment with the FABP4 selective inhibitor BMS309403 alleviated lipopolysaccharide induce acute liver injury and high fat diet-induced NASH in mice (65), and a knockout of FABP4 reduces fibrosis in CCl4 and bile duct ligation model in mice (58).